hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06290167, orgStudyIdInfo id: 30M201, briefTitle: A New 360° Dual-task Based Protocol for the Pre-clinical In-hospital and At-home Rehabilitation of Elderly: DUAL-Rehab, acronym: DUAL-Rehab, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-03, primaryCompletionDateStruct date: 2026-04-10, completionDateStruct date: 2026-04-10, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Istituto Auxologico Italiano, class: OTHER, descriptionModule briefSummary: The main objective of this project is two-fold1. to develop a Dual-Task training exploiting the potentiality of the 360° technology in terms of interactivity and ecological validity2. to investigate its efficacy in improving the cognitive functioning in a randomized clinical trial for 2 different populations: subjects with subjective memory complaints and mild cognitive impairment.Specifically, participants will follow an integrated training including 2 phases: 1)in-hospital rehabilitation, where subjects will be provided sessions of the training in immersive modality; 2)at-home rehabilitation, where older adults will be asked to perform at home the non-immersive version of the training using a tablet.Expected outcome is an improvement in cognitive functioning (assessed with a complete neuropsychological battery) after the training, thus advancing literature about non-pharmacological interventions in the preclinical stages of dementia along with innovative technical instruments., conditionsModule conditions: Cognitive Decline, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: FACTORIAL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: 360° media, interventions name: Treatment As Usual (TAU), interventions name: In hospital sessions, interventions name: at home sessions, interventions name: Mild Cognitive Impairment, interventions name: Subjective Memory Complain, outcomesModule primaryOutcomes measure: Cognitive functions, primaryOutcomes measure: Motor functions, eligibilityModule sex: ALL, minimumAge: 65 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istituto Auxologico Italiano IRCCS, status: RECRUITING, city: Milan, state: MI, zip: 20149, country: Italy, contacts name: Elisa Pedroli, PsyD, role: CONTACT, phone: 02 61911 2707, email: e.pedroli@auxologico.it, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06290154, orgStudyIdInfo id: RG2024-022-02, briefTitle: Factors Associated With Posttransplant Cardiac Outcomes, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Sun Yat-sen University, class: OTHER, descriptionModule briefSummary: Cardiovascular disease has become the leading cause of death early after liver transplantation (LT). The aging LT population is accompanied with the increasing prevalence of cardiovascular risk factors such as hypertension, diabetes, and hyperlipidemia. Furthermore, cirrhosis has been known to cause alterations in the systemic haemodynamic system and cardiac muscle dysfunction, systolic and/or diastolic, known as Cirrhotic cardiomyopathy (CCM). Hence, transthoracic echocardiography is required in all LT candidates for preprocedural evaluation and risk stratification. However, traditional echocardiographic indices of cardiac function have low sensitivity. It is unclear whether comprehensive echocardiographic multiparameters, including speckle tracking echocardiograph (STE) and tissue doppler imaging (TDI) can help improve preoperative risk stratification. Therefore, we sought to analyze the ability of clinical and comprehensive echocardiography variables to predict intraoperative and perioperative cardiac events and cardiac mortality in our LT patient experience up to early post-liver transplant., conditionsModule conditions: Cardiovascular Diseases, conditions: Liver Transplantation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, outcomesModule primaryOutcomes measure: a composite outcome of new cardiovascular disease after liver transplantation, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06290115, orgStudyIdInfo id: 202301, briefTitle: Adolescents' Non-suicidal Behavior and Perception of Parents' Negative Emotional Expression and Family Communication, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-10-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Sun Yat-sen University, class: OTHER, descriptionModule briefSummary: The starting point of this project is to study young people and adolescents, aiming to explore the correlation between non-suicidal behavior of young people and adolescents and the negative emotional expression of their parents and family communication. The purpose of this project is to investigate the non-suicidal self-injury behavior of teenagers aged 15-25 years by issuing questionnaires (sample size: 327 people). In order to find out whether there is any connection between family communication and non-suicidal self-injury behavior of young people and adolescents., conditionsModule conditions: Adolescents, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 324, type: ESTIMATED, armsInterventionsModule interventions name: Questionnaires set 1, interventions name: Questionnaires set 2, interventions name: Questionnaires set 3, outcomesModule primaryOutcomes measure: Non-suicidal self-injury behavior of young people and adolescents, primaryOutcomes measure: Expression of negative emotions of parents, primaryOutcomes measure: Parent-Adolescent communication scale, secondaryOutcomes measure: Childhood Trauma Questionnaire, secondaryOutcomes measure: Parental Bongding Instrument, secondaryOutcomes measure: The parent-child relationship intimacy scale, eligibilityModule sex: ALL, minimumAge: 15 Years, maximumAge: 25 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06290089, orgStudyIdInfo id: OEV-131, briefTitle: Pre-Study of Wild Type Enterotoxigenic E. Coli (ETEC) Strain for Verification of a Planned Challenge Dose, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-12, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Scandinavian Biopharma AB, class: INDUSTRY, collaborators name: Johns Hopkins Bloomberg School of Public Health, descriptionModule briefSummary: This is an open label study with the aim to estimate the incidence of moderate and severe diarrhea among participants challenged with an enterotoxigenic E. coli (ETEC) strain. This strain is planned to be used in a subsequent challenge study on the efficacy of an oral inactivated ETEC vaccine.The study will be conducted at one site; the Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland, United States., conditionsModule conditions: ETEC Diarrhea, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Enterotoxigenic E. coli (ETEC) strain, outcomesModule primaryOutcomes measure: The incidence of moderate and severe diarrhea, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, status: RECRUITING, city: Baltimore, state: Maryland, zip: 21205, country: United States, contacts name: Kawsar R. Talaat, MD, role: CONTACT, phone: 410-502-9627, email: ktalaat@jhu.edu, contacts name: Kawsar R. Talaat, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.29038, lon: -76.61219, hasResults: False
protocolSection identificationModule nctId: NCT06290076, orgStudyIdInfo id: IAT-PROACT, briefTitle: A Predictive Model and Scoring System for Severe Complications After Endovascular Thrombectomy, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-01-01, primaryCompletionDateStruct date: 2023-06-30, completionDateStruct date: 2023-09-30, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Xuanwu Hospital, Beijing, class: OTHER, descriptionModule briefSummary: To establish a predictive model and scoring system for predicting severe complications after thrombectomy. This scoring system can be used to identify high-risk patients after endovascular thrombectomy, guide the early use of adjunctive interventions, and provide reference for future clinical trials., conditionsModule conditions: Acute Ischemic Stroke, conditions: Endovascular Thrombectomy, conditions: Symptomatic Intracranial Hemorrhage, conditions: Malignant Cerebral Edema, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1500, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Rate of severe complications, secondaryOutcomes measure: Rate of mRS score of 3-6, secondaryOutcomes measure: Rate of mRS score of 5-6, secondaryOutcomes measure: Rate of symptomatic intracranial hemorrhage, secondaryOutcomes measure: Rate of malignant cerebral edema, secondaryOutcomes measure: Change of NIHSS score, secondaryOutcomes measure: Rate of modified Rankin Scale (mRS) score of 0-2, secondaryOutcomes measure: All-cause mortality, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Xuanwu Hospital, Capital Medical University, city: Beijing, state: Beijing, zip: 100053, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06290063, orgStudyIdInfo id: 22-08-0138, briefTitle: Cannabidiol and Older Adult Cannabis Users, acronym: QUARTz, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2028-08-31, completionDateStruct date: 2028-08-31, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: University of Colorado, Boulder, class: OTHER, descriptionModule briefSummary: Cannabis use increased 10 fold among adults over the age of 65 between 2014 and 2016 but very little data exists on the extent of their harmful effects on health and behavior. The overarching goal of this project is to test a novel harm reduction strategy in which older individuals who seek to use cannabis for pain, anxiety or mood problems (depression/anxiety) will be randomly assigned to one of three conditions in an 8 week randomized controlled trial: hemp-derived CBD+THC, hemp-derived CBD-THC, or placebo. This work has the ability to directly inform individual choices regarding the use of cannabis products among older adults, and direct policy decisions regulating cannabis formulations on the legal market., conditionsModule conditions: Sleep, conditions: Anxiety, conditions: Depression, conditions: Pain, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 385, type: ESTIMATED, armsInterventionsModule interventions name: fsCBD Cannabidiol, interventions name: bsCBD Cannabidiol, interventions name: Placebo, outcomesModule primaryOutcomes measure: Subjective Motor Function, primaryOutcomes measure: Balance, primaryOutcomes measure: Anxiety, primaryOutcomes measure: Depression, primaryOutcomes measure: Blood Cytokine Levels, primaryOutcomes measure: Depression/Anxiety, primaryOutcomes measure: Drug Effects, primaryOutcomes measure: Inhibitory Control, primaryOutcomes measure: Cognitive Function, primaryOutcomes measure: Pain Intensity and Interference, primaryOutcomes measure: Cognitive Ability, primaryOutcomes measure: Pain Intensity, primaryOutcomes measure: Change in Condition, primaryOutcomes measure: Sleep Disturbance, primaryOutcomes measure: Sleep-Related Impairment, primaryOutcomes measure: Memory, secondaryOutcomes measure: Polypharmacy-Pain Medications, secondaryOutcomes measure: Polypharmacy-Psychiatric Medications, secondaryOutcomes measure: Polypharmacy-Sleep Medications, secondaryOutcomes measure: Strength and Endurance, secondaryOutcomes measure: Sleep Quality, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Colorado at Boulder, city: Boulder, state: Colorado, zip: 80309, country: United States, contacts name: Ellie Sundali, BA, role: CONTACT, email: ellie.sundali@colorado.edu, geoPoint lat: 40.01499, lon: -105.27055, hasResults: False
protocolSection identificationModule nctId: NCT06290050, orgStudyIdInfo id: TAK-279-1006, briefTitle: A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-29, primaryCompletionDateStruct date: 2024-05-03, completionDateStruct date: 2024-05-16, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Takeda, class: INDUSTRY, descriptionModule briefSummary: The main aim of this study is to find out how several doses of TAK-279 affects the body of healthy adults and processes midazolam and repaglinide (pharmacokinetics or PK). Another aim is to learn about the side effects of TAK-279 and how well it is tolerated when given to healthy adults either alone or together with midazolam or repaglinide.During the study, participants will need to stay at the clinic for 19 days. Blood samples will be taken at several timepoints during the study. The study drug will be given by mouth (orally)., conditionsModule conditions: Healthy Volunteers, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Midazolam, interventions name: Repaglinide, interventions name: TAK-279, outcomesModule primaryOutcomes measure: Cmax: Maximum Observed Plasma Concentration for Midazolam and Repaglinide When Administered Alone and With TAK-279, primaryOutcomes measure: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Midazolam and Repaglinide When Administered Alone and With TAK-279, primaryOutcomes measure: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Midazolam and Repaglinide When Administered Alone and With TAK-279, secondaryOutcomes measure: Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESI), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Celerion, status: RECRUITING, city: Tempe, state: Arizona, zip: 85283, country: United States, contacts name: Study Contact, role: CONTACT, phone: 480-415-7404, email: mara.baier@celerion.com, contacts name: Mara Baier, DO, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.41477, lon: -111.90931, hasResults: False
protocolSection identificationModule nctId: NCT06290037, orgStudyIdInfo id: 2024-01-003, briefTitle: Driving Ability Evaluation System to Improve the Conditional Driving License System: Feasibility Study of High-risk Drivers., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Seoul National University Hospital, class: OTHER, descriptionModule briefSummary: The primary objective of this study is to verify the safety and validity of a VR driving simulator developed for evaluating the driving abilities of elderly drivers.This study also aims to establish indicators in VR driving simulator to evaluate high-risk group for driving, such as cognitive and physical abilities. Therefore, this study aims to measure the physical driving function, general physical function and cognitive function of elderly drivers. to identify the correlation between their outcomes and the VR driving simulator's result, conditionsModule conditions: Automobile Driving, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: VR Driving Simulator, interventions name: Computerized Neurocognitive Function Test, interventions name: Driver Test Station, interventions name: Short Physical Performance Battery, interventions name: On-road field driving Test, outcomesModule primaryOutcomes measure: Feasibility of VR driving simulator, primaryOutcomes measure: Driving performance in simulator, measured by driving errors, eligibilityModule sex: ALL, minimumAge: 65 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Seoul National University Hospital, status: RECRUITING, city: Seoul, country: Korea, Republic of, contacts name: Ja-Ho Leigh, M.D. Msc., role: CONTACT, email: mazican@gmail.com, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06290024, orgStudyIdInfo id: XH-23-013, briefTitle: A Multi-center Clinical Longitudinal Study of Neuropathic Pain by Collecting Data, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-08-15, primaryCompletionDateStruct date: 2024-08-15, completionDateStruct date: 2024-08-15, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, class: OTHER, descriptionModule briefSummary: A multi-center clinical longitudinal study of neuropathic pain by collecting data on patients' brain physiology and cognitive function, conditionsModule conditions: Pain, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: OTHER, enrollmentInfo count: 2000, type: ESTIMATED, armsInterventionsModule interventions name: A multi-center clinical longitudinal study of neuropathic pain by collecting data on patients' brain physiology and cognitive function, outcomesModule primaryOutcomes measure: Visual Analogue Scale/Score（VAS）, primaryOutcomes measure: digital pain grading method (NRS), primaryOutcomes measure: neuropathic pain assessment scale (DN4), primaryOutcomes measure: sleep quality (Pittsburgh sleep quality index, Ascens insomnia scale), primaryOutcomes measure: EEG, primaryOutcomes measure: Barrett impulse scale (BIS), primaryOutcomes measure: (Generalized Anxiety Disorder,GAD-7), primaryOutcomes measure: (Patient Health Questionnaire-9, secondaryOutcomes measure: Montreal cognitive assessment scale (MoCA), secondaryOutcomes measure: ocial support assessment scale (SSQ), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ke Ma, status: RECRUITING, city: Shanghai, state: Yangpu, zip: 200092, country: China, contacts name: Ke NA Ma, PHD, role: CONTACT, phone: 13361879260, email: marke72@163.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06290011, orgStudyIdInfo id: XH-23-014, briefTitle: A Clinical Study on the Efficacy of Cognitive Distraction Focus Relaxation Therapy Based on MR, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-11, primaryCompletionDateStruct date: 2024-10-11, completionDateStruct date: 2024-10-11, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, class: OTHER, descriptionModule briefSummary: A prospective, single blind, randomized, parallel controlled trial was conducted to evaluate the analgesic effect and safety of MR based "cognitive distraction focus relaxation therapy" in patients clinically diagnosed with chronic moderate to severe pain, conditionsModule conditions: Pain, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: OTHER, enrollmentInfo count: 132, type: ESTIMATED, armsInterventionsModule interventions name: Pain key group, outcomesModule primaryOutcomes measure: Visual Analogue Scale/Score（VAS）, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ke Ma, status: RECRUITING, city: Shanghai, state: Yangpu, zip: 200092, country: China, contacts name: Ke NA Ma, PHD, role: CONTACT, phone: 13361879260, email: marke72@163.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False